The White House has directed visa officers to consider common health ailments, including obesity and diabetes, when deciding ...

The 72-week multinational phase 3 ATTAIN-2 trial randomized 1613 participants with obesity or overweight (BMI ≥ 27.0) and T2D ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

US visas will soon be out of reach to applicants suffering from any chronic illness or medical conditions like diabetes or ...

MAHA advocates are skeptical of President Donald Trump's deal to lower drug prices for GLP-1 anti-obesity drugs.

Foreign nationals applying for a visa to live in the US might be rejected if they have health conditions such as diabetes or ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a ...

The same survey also found that weight loss drugs such as Ozempic and Wegovy – known as GLP-1 ( glucagon-like peptide-1) ...

The guidance describes obese foreigners as a ‘public charge’ and orders visa officers to guess how much they would claim in ...

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.

Obesity products gain momentum in India and globally as multinationals leverage smart pricing and collaborations amidst ...

About one in ten people globally live with diabetes, and cardiovascular diseases remain the leading cause of death worldwide.